Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, University of Kentucky to Collaborate on Ovarian Cancer Dx

NEW YORK, AUG, 24 (GenomeWeb News) - Ciphergen Biosystems and the University of Kentucky have signed a research and collaboration agreement that will allow the Ciphergen to exclusively license discoveries from partnership's ovarian cancer research for use in diagnostics, Ciphergen said today.

 

According to Paul DePriest, an associate professor of obstetrics and gynecology at UK, the university hopes that the partnership will "accelerate the development of a new diagnostic approach to ovarian cancer" by pairing UK's clinical expertise with Ciphergen's "biomarker discovery and diagnostic process."

 

Ciphergen will be providing UK with its suite of proteomic tools to help researchers analyze patients' tumor cyst fluid and blood for biomarker discovery and development of assays, the company said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.